<DOC>
	<DOCNO>NCT01056549</DOCNO>
	<brief_summary>Exenatide acutely inhibit intestinal lipoprotein particle production . We unable speculate whether exenatide affect hepatic lipoprotein production human since currently evidence animal model vitro study demonstrate effect</brief_summary>
	<brief_title>Exenatide ( Byetta ® ) Regulation Intestinal Hepatic Lipoprotein Particle Production Humans</brief_title>
	<detailed_description>Subjects receive infusion stable isotope enrich acetate , leucine bolus glycerol order measure rate fatty acid synthesis , apolipoprotein triglyceride turnover respectively . This vivo stable isotope enrichment methodology widely establish used investigator around world 30 year examine metabolism various metabolite human . Following overnight fast , approximately 9am day 1 study subject admit hospital 30ml fasting blood sample drawn analysis plasma glucose , total plasma cholesterol , LDL-cholesterol , HDL cholesterol , triglyceride ( TG ) , free fatty acid ( FFA ) , insulin , GLP-1 , growth hormone , glucagon , stable isotope enrichment detailed analysis triglyceride rich lipoprotein ( TRL ) composition ( lipid apolipoprotein content ) . A radio-opaque polyvinyl feed tube ( Entriflex NG Tube 55 '' [ 140cm ] 10fr Item # 8884721055 , Kendall Products , Tyco Healthcare , Toronto , ON ) insert nose stomach , enough length provide migration tip duodenum . The subject administer 10 mg metoclopramide orally facilitate transport tip tube duodenum . The subject allow eat regular meal day fast overnight 7pm remain fasting duration study . Water ad lib allow . At approximately 3pm day 1 abdominal X-Ray confirm position tube duodenum . At 4pm 2 iv 's inserted superficial vein forearm , one infusion one sampling . An infusion 1-13C acetate ( 15 gm bag ½ N saline 32ml/hr ) begin iv 's insert infused remainder study , 27 hour . Starting 4am synthetic triglyceride emulsion , Intralipid ( 20 % solution , Baxter Canada ) , infuse feed tube duodenum rate 40 ml/hr duration experiment ( ie 7pm evening ) . This provide steady state feed state subsequent assessment lipoprotein turnover kinetics . The subject receive , random order , either exenatide 10 mg equivalent volume saline subcutaneously 7am day 2 hospitalization ( i.e . -2hr ) first two study . The pancreatic clamp begin 7am ( -2hr ) , immediately follow administration either exenatide saline continue throughout subsequent 12 hour ( 7pm ) . . During pancreatic clamp subject receive iv infusion glucagon ( 0.65ng/kg/min ) , growth hormone ( Humatrope , 3.0 ng/kg/min ) , somatostatin ( sandostatin , 25 µg/hr ) insulin ( Novolin R , 0.05 mU/kg/min ) . At 9 ( refer time point 0hr lipoprotein turnover study ) , lipoprotein turnover study begin . An iv bolus deuterated-glycerol ( d5-glycerol , 75 mmol/kg ) administer , follow primed-constant infusion deuterated leucine ; d3-leucine , ( 10 mmol/kg bolus follow 10 mmol/kg/hr 10 hour ) . Blood sample collect prior regular time interval 10 hour iv bolus d3-glycerol start constant infusion d3-leucine ( assessment lipoprotein kinetics ) . Blood sample collect prior ( 30ml -2hr , 10ml -1hr 30ml 0hr ) 5min 15min ( 10ml ) 30ml 30min , 1hr , 2hr , 3hr , 4hr , 5hr , 6hr ( 10ml ) ,7hr , 8hr , 9hr 10hr administration d5-glycerol start d3-leucine infusion .</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>1 . Men woman , age 18 60 year 2 . Body mass index 20 kg/m2 25 kg/m2 3 . Hemoglobin 130g/L . 4 . Normal glucose tolerance response 75g , 2hr OGTT 1 . Subject history hepatitis/hepatic disease active within previous two year . 2 . Any significant active ( past 12 month ) disease gastrointestinal , pulmonary , neurological , renal ( Cr &gt; 1.5 mg/dL ) , genitourinary , hematological system , severe uncontrolled treated untreated hypertension ( sit diastolic BP &gt; 100 systolic &gt; 180 ) proliferative retinopathy 3 . History diabetes OGTT indicative diabetes impair glucose tolerance . 4 . Any history MI clinically significant , active , cardiovascular history include history arrhythmia 's conduction delay ECG , unstable angina , decompensated heart failure . 5 . Any laboratory value : AST &gt; 2x ULN ; ALT &gt; 2x ULN TSH &gt; 6 mU/l 6 . Current addiction alcohol substance abuse determine investigator . 7 . Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation 8 . Taking prescription nonprescription medication time study 9 . Having donate blood three month prior three month post study procedures 10 . A pregnancy test perform 1 3 day prior study female subject . Those test positive pregnancy exclude . 11 . No clinical evidence neoplasm know overexpress GLP1 receptor i.e . pheochromocytoma , brain tumor embryonic tumor . 12 . Hypersensitivity egg , soya , peanut protein previous allergy intralipid 13 . Those known sensitivity metoclopramide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Intestinal lipoprotein</keyword>
	<keyword>Apo B48 apoB100</keyword>
	<keyword>Pancreatic clamp</keyword>
	<keyword>GLP-1 agonist</keyword>
</DOC>